19 June 2013
Keywords: ARIAD Pharma, Ridaforolimus, Merck & Co, Sarcoma, Ponatinib, Leukemia
Article | 21 March 2011
ARIAD Pharmaceuticals (Nasdaq: ARIA) saw its shares jump 5.5% to $5.93 when it revealed that it has opted to exercise its option ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
21 March 2011
22 March 2011
© 2013 thepharmaletter.com